With the approval of tovorafenib by $DAWN, it’s worth celebrating the long journey of R&D in our business. Others have written on this better (@JacobPlieth @SFBIZronleuty), but here’s the short story: The molecule was discovered in a collaboration between Sunesis & Biogen that started 20 years ago. Biogen deprioritized oncology under CEO Scangos and stopped working on RAF in 2010, reverting rights back to Sunesis. But tovo was covered by key patents from the collaboration, which were assigned to Sunesis. Fwiw, two of the co-inventors of tovo later became Atlas entrepreneurs: Gnanasambandam Kumar Kumaravel (Padlock) and Alexey Lugovsky (Diagonal). Small world of both the Biogen diaspora and the @atlasventure network. Takeda licensed it from Sunesis in 2011, and over next 6-7 years its clinical work in melanoma failed to deliver. Physician-scientist/pediatric oncologist @drsam co-founded Day One with @JuliePapanek in 2019 to focus on pediatric cancer. They license tovo from Takeda in 2020, and my partner @MikeNGladstone convinced Atlas to join Canaan Partners in the $60M Series A, as did Access Industries. Company goes public in a 2021 IPO. Sunesis retained some economics in tovo. It did a reverse merger in 2021, and became Viracta. It sold its tovo milestones/royalties to Xoma later that year. After the success of Firefly-1 in pediatric LGG, tovo (Ojemda) was granted accelerated approval, with the ongoing Phase 3 Firefly-2 study underway. Amazing journey, with many teams participating along the way. It takes a village... or at least a collaborative ecosystem... to bring drugs to patients.